COLUMBUS, Ohio, Aug. 6, 2024
/PRNewswire/ -- Andelyn Biosciences, Inc., a leading and
patient-focused cell and gene therapy Contract Development and
Manufacturing Organization (CDMO), has entered into a License
Agreement with the Broad Institute to expand its AAV
CuratorTM Platform offering to include MyoAAV plasmids.
Developed by researchers at the Broad Institute of MIT and Harvard, this
new family of plasmids produce adeno-associated viruses (AAVs) that
are ten times more efficient in reaching muscle tissue than
wild-type vectors, while also de-targeting the liver. With more
precise targeting of muscle tissue, research shows MyoAAV-delivered
therapies may require lower dosing.
The License Agreement allows Andelyn to use the MyoAAV plasmids
to perform research and development services for its clients who
are developing gene therapies to screen potential candidates at
Andelyn and to perform scale-up and pre-clinical development work
in preparation for IND-enabling studies. The Agreement also permits
Andelyn to sublicense the MyoAAV plasmids to its clients for
internal research purposes.
Andelyn's expertise in translational drug development will bring
Broad's new class of engineered AAVs to biotech organizations
targeting diseases in these therapeutic areas where there is still
a significant unmet need. This capability will ultimately reduce
the effective dose demand and improve product safety. Incorporating
MyoAAVs into Andelyn's AAV CuratorTM Platform will drive
sustainable manufacturing practices and continue to bring more
accessible treatments to patients.
Matt Niloff, Chief Commercial
Officer of Andelyn, said, "Our license from the Broad Institute
furthers our goal of providing the industry access to critical
tools and capabilities that facilitate the development of
innovative therapies to bring more treatments to more patients.
With access to the increased specificity of MyoAAVs, our clients
now have the opportunity to maximize efficiency in their gene
therapy processes and drive down the cost per patient."
With the highest quality standards and scalable end-to-end
development and manufacturing capabilities across its Columbus, Ohio facilities, Andelyn is enabling
the progression of life-altering gene therapies for rare and
prevalent diseases.
About Andelyn Biosciences, Inc.
Andelyn Biosciences is
a full-service cell and gene therapy CDMO focused on the
development, characterization and production of viral vectors for
gene therapy. With more than 20 years of experience, Andelyn's deep
scientific expertise has resulted in the production of cGMP
material for more than 450 clinical batches and 75 global clinical
trials. Operating out of three Columbus,
Ohio facilities, Andelyn supports its clients in developing
cell and gene therapies from concept through plasmid engineering
and manufacturing, process and analytical development, and cGMP
clinical and commercial manufacturing. Andelyn can accelerate
programs and deliver high quality products by developing and
manufacturing processes on its configurable, data-driven AAV
CuratorTM Platform, or tech transfer in an established
client program. Capabilities include cGMP manufacturing for both
adherent and suspension processes up to a 2,000-liter capacity. A
rigorous quality system, regulatory support, and supply chain
vertical integration further support clients in bringing their
critical therapies to market. For more information, visit
andelynbio.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/andelyn-biosciences-expands-aav-curator-platform-offering-to-include-myoaav-plasmids-through-a-license-agreement-from-the-broad-institute-of-mit-and-harvard-302215518.html
SOURCE Andelyn Biosciences